FDA Class II Classification for Amblyopia Digital Therapy Devices

Published April 29, 2026 | By Jared Clark, JD, MBA, PMP, CMQ-OE, CQA, CPGP, RAC — Principal Consultant, Certify Consulting

The FDA published a final order on April 22, 2026, classifying the digital therapy device for amblyopia into Class II under 21 CFR Part 886. If you are developing or already marketing a software-based treatment for amblyopia — sometimes called "lazy eye" — this classification directly shapes the regulatory pathway your product must follow. Special controls now apply. That means if you have been operating under a different assumption about your device's class, it is time to revisit your regulatory strategy.

Here is what changed, what it requires, and how to bring your program into alignment before this becomes a problem.

What Is a Digital Therapy Device for Amblyopia?

Amblyopia is the most common cause of visual impairment in children, affecting an estimated 2–3% of the population globally, or roughly 3 million children in the United States alone. Traditional treatment has relied on patching or atropine eye drops. The newer generation of digital therapy devices delivers software-based binocular stimulation — typically through a game-like interface — to train the brain to use both eyes more equally.

These devices sit squarely at the intersection of Software as a Medical Device (SaMD) and ophthalmic therapeutics, which has made their regulatory classification a genuinely complex question. FDA's final order resolves that question.

What the FDA Actually Did

The FDA issued a final administrative order classifying the digital therapy device for amblyopia into Class II (Special Controls), effective April 22, 2026. The order is published at 86 FR [2026-07861] and amends 21 CFR Part 886 (Ophthalmic Devices) by adding a new device classification.

Under 21 CFR 860.7, Class II devices are those for which general controls alone are insufficient to provide reasonable assurance of safety and effectiveness, but for which there is enough information to establish special controls that do provide that assurance. In plain terms: FDA is saying this device type is manageable with the right guardrails, and they have now defined what those guardrails are.

This was not a premarket approval (PMA) pathway determination — that would be Class III. Class II means the primary route to market is 510(k) clearance, with compliance to the special controls as part of demonstrating substantial equivalence.

The Special Controls: What They Require

This is where manufacturers need to spend most of their attention. Special controls for a newly classified device type are not boilerplate. They are device-specific requirements that reflect FDA's understanding of the particular risks the device presents. Based on the classification order, the special controls for digital amblyopia therapy devices address several areas:

Performance Testing and Clinical Evidence

Manufacturers must provide clinical performance data demonstrating that the device achieves its intended therapeutic effect — improving visual acuity and binocular function in the amblyopic eye — without causing adverse visual effects. This typically means controlled clinical study data, not just bench testing.

Patient Population Specificity

Because amblyopia treatment is most effective and most risky in specific age windows (primarily children under 10), the special controls require that labeling and clinical evidence clearly address the intended patient population. Pediatric use claims carry additional scrutiny.

Cybersecurity and Software Documentation

Digital therapy devices are SaMD, and FDA's expectations for software documentation have grown substantially since the 2023 Cybersecurity Guidance and the requirements embedded in the Consolidated Appropriations Act of 2023. The special controls will require a Software Bill of Materials (SBOM), a cybersecurity risk management plan, and post-market surveillance commitments for software updates.

Usability and Human Factors

Given that the primary users are children (and their caregivers as secondary users), human factors validation is a meaningful control. Manufacturers must demonstrate that the interface does not introduce errors that could lead to under-treatment, overuse, or misapplication.

Labeling Requirements

The order specifies labeling must include the intended use population, contraindications (including photosensitive epilepsy, given the visual stimulation involved), instructions for caregiver supervision, and a clear description of how the device fits within a broader treatment plan supervised by a licensed eye care professional.

Comparison: Class I vs. Class II vs. Class III for Digital Ophthalmic Devices

Understanding where this classification lands in context matters, especially if you are evaluating predicate strategy.

Most digital health companies entering the amblyopia space were likely anticipating either a De Novo pathway (if no predicate existed) or a 510(k) against an existing cleared device. With this classification order in place, the 510(k) pathway is now codified, which actually simplifies the strategic picture — provided you can meet the special controls.

What Changed — and Why It Matters for Your 510(k) Strategy

Before this order, a manufacturer seeking clearance for a digital amblyopia therapy device had to navigate FDA's SaMD policy guidance, the De Novo process if no predicate existed, and general ophthalmic device regulations, without a dedicated product code or classification regulation to anchor the submission. That ambiguity created real risk in predicate selection and substantial equivalence arguments.

The classification order establishes a new product code under 21 CFR Part 886 and creates a defined regulatory home for this device type. That is genuinely useful. It means:

1. Your 510(k) now has a clear regulation to cite as the basis for classification.
2. The special controls define the minimum performance and documentation bar you must meet — no guessing.
3. Future predicates are now traceable, so the second and third 510(k) submissions in this space will be able to point to cleared devices.

The effective date of April 22, 2026 is the date the classification regulation becomes final. Devices already on the market under a prior clearance or De Novo authorization are not automatically out of compliance — but manufacturers of those devices should review whether their existing documentation and labeling align with the new special controls and address any gaps proactively.

Practical Compliance Guidance: Where to Start

If you are a manufacturer, here is how I would approach this in order of priority.

Step 1: Determine whether this classification applies to your device. The critical question is intended use. Is your device intended to treat amblyopia through digital, software-based visual stimulation? If yes, this classification almost certainly covers you. If your device is diagnostic only (measuring visual acuity, for example), you are in a different classification bucket.

Step 2: Review your existing 510(k) or De Novo authorization against the new special controls. If you are already cleared, map your current technical documentation, labeling, and clinical evidence against each special control listed in the order. Gaps should be addressed through your CAPA system and documented in your Device History File (DHF) and Design History File (DHF).

Step 3: Update your Quality Management System. Your ISO 13485-compliant QMS should reflect the new regulatory requirements. Specifically, review your design controls procedure and confirm it captures the human factors validation and software lifecycle requirements the special controls demand. If your QMS is not already structured to support SaMD development, this is the moment to fix that.

Step 4: Assess your clinical data package. The special controls require clinical performance data. If you have it, make sure it is formatted and documented in a way that would hold up in a 510(k) review. If you do not have it, that is your longest lead-time item — start now.

Step 5: Prepare your cybersecurity documentation. An SBOM and a cybersecurity risk management plan are not trivial documents to produce after the fact. If you are in development, build these into your design controls from the outset. If you are already on the market, conduct a cybersecurity gap assessment against FDA's 2023 guidance and the expectations embedded in the special controls.

The Broader Signal: FDA Is Getting Specific About Digital Therapeutics

This classification is not happening in isolation. FDA has been steadily moving toward more defined regulatory homes for digital health products — away from the ambiguity that characterized the early SaMD era. In 2023, FDA issued final guidance on cybersecurity for medical devices. In 2024 and 2025, several De Novo authorizations in the digital therapeutics space generated new product codes. The amblyopia classification order continues that pattern.

What FDA is signaling, in my view, is that the digital therapeutics space is maturing enough that device-specific classification regulations are warranted. That is good news for manufacturers who are willing to do the documentation work, because it reduces the regulatory uncertainty that has made investors and manufacturers nervous. The companies that move quickly to align with these special controls will find the 510(k) pathway more predictable, not less.

According to the FDA's own data, the 510(k) program cleared approximately 3,500 devices in fiscal year 2023, with SaMD submissions representing a growing share of that total. The amblyopia classification adds one more product type to a pathway that, for all its complexity, has a well-established track record of getting innovative devices to market.

Key Dates and Deadlines

There is no explicit grace period for existing devices articulated in the order — which means the clock is running. If you are on the market under a prior authorization and your documentation does not currently align with the new special controls, the responsible path is a documented gap assessment and a remediation plan.

A Note on Predicate Strategy for New Entrants

One of the more practical implications of this classification order is predicate strategy for companies that have not yet submitted a 510(k). Prior to this order, predicates in the digital amblyopia space were sparse and the substantial equivalence argument required careful construction. Now, the classification regulation itself is the anchor.

That said, a cleared predicate device will still be valuable — and as the first 510(k) clearances come through under this new product code, they will become the natural predicates for later submissions. If you are in the queue now, you may be building the predicate that others rely on. Make sure your submission is as complete and well-documented as possible, because it will shape what comes after.

How Certify Consulting Can Help

At Certify Consulting, I have worked with 200+ medical device companies navigating exactly this kind of regulatory shift — a new classification, a changed pathway, a product that needs to be repositioned in the submission queue. Our track record speaks for itself: 100% first-time audit pass rate across eight-plus years of practice, including digital health and SaMD clients.

If you have a digital therapy device for amblyopia — or a product in adjacent digital therapeutics categories — and you want to pressure-test your regulatory strategy against the new special controls, I am happy to talk through it. You can reach us at certify.consulting.

You can also review our ISO 13485 QMS resources to ensure your quality system is set up to support the documentation demands this classification imposes.

Last updated: 2026-04-29

Source: Federal Register, Vol. 91, 2026-07861 — Medical Devices; Ophthalmic Devices; Classification of the Digital Therapy Device for Amblyopia (April 22, 2026)